789 related articles for article (PubMed ID: 21350488)
1. Programming the magnitude and persistence of antibody responses with innate immunity.
Kasturi SP; Skountzou I; Albrecht RA; Koutsonanos D; Hua T; Nakaya HI; Ravindran R; Stewart S; Alam M; Kwissa M; Villinger F; Murthy N; Steel J; Jacob J; Hogan RJ; García-Sastre A; Compans R; Pulendran B
Nature; 2011 Feb; 470(7335):543-7. PubMed ID: 21350488
[TBL] [Abstract][Full Text] [Related]
2. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
4. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
[TBL] [Abstract][Full Text] [Related]
5. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
6. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
[TBL] [Abstract][Full Text] [Related]
7. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.
Wei CJ; Boyington JC; McTamney PM; Kong WP; Pearce MB; Xu L; Andersen H; Rao S; Tumpey TM; Yang ZY; Nabel GJ
Science; 2010 Aug; 329(5995):1060-4. PubMed ID: 20647428
[TBL] [Abstract][Full Text] [Related]
8. TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice.
Jeisy-Scott V; Kim JH; Davis WG; Cao W; Katz JM; Sambhara S
J Virol; 2012 Oct; 86(20):10988-98. PubMed ID: 22837197
[TBL] [Abstract][Full Text] [Related]
9. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
[TBL] [Abstract][Full Text] [Related]
10. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene.
Kamlangdee A; Kingstad-Bakke B; Anderson TK; Goldberg TL; Osorio JE
J Virol; 2014 Nov; 88(22):13300-9. PubMed ID: 25210173
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
van der Velden MV; Geisberger A; Dvorak T; Portsmouth D; Fritz R; Crowe BA; Herr W; Distler E; Wagner EM; Zeitlinger M; Sauermann R; Stephan C; Ehrlich HJ; Barrett PN; Aichinger G
Clin Vaccine Immunol; 2014 Jun; 21(6):867-76. PubMed ID: 24739978
[TBL] [Abstract][Full Text] [Related]
12. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.
van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H
Front Immunol; 2018; 9():2350. PubMed ID: 30369928
[TBL] [Abstract][Full Text] [Related]
13. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
14. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
15. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
16. Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production.
Li C; To KKW; Zhang AJX; Lee ACY; Zhu H; Mak WWN; Hung IFN; Yuen KY
Front Immunol; 2018; 9():2370. PubMed ID: 30369932
[TBL] [Abstract][Full Text] [Related]
17. A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.
Sato-Kaneko F; Yao S; Lao FS; Shpigelman J; Messer K; Pu M; Shukla NM; Cottam HB; Chan M; Chu PJ; Burkhart D; Schoener R; Matsutani T; Carson DA; Corr M; Hayashi T
Front Immunol; 2020; 11():1207. PubMed ID: 32636840
[TBL] [Abstract][Full Text] [Related]
18. A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice.
Zheng L; Wang F; Yang Z; Chen J; Chang H; Chen Z
BMC Infect Dis; 2009 Feb; 9():17. PubMed ID: 19216752
[TBL] [Abstract][Full Text] [Related]
19. Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine.
Nakayama M; Shichinohe S; Itoh Y; Ishigaki H; Kitano M; Arikata M; Pham VL; Ishida H; Kitagawa N; Okamatsu M; Sakoda Y; Ichikawa T; Tsuchiya H; Nakamura S; Le QM; Ito M; Kawaoka Y; Kida H; Ogasawara K
PLoS One; 2013; 8(12):e82740. PubMed ID: 24376571
[TBL] [Abstract][Full Text] [Related]
20. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
